Pulmatrix and Cullgen are pursuing a merger, supporting each other while exploring alternatives, seeking approval from China Securities Regulatory Commission.

Pulmatrix, headquartered in FRAMINGHAM, Mass., is showing ongoing support for Cullgen in their efforts to gain approval for their merger from the China Securities Regulatory Commission. The merger involves Pulmatrix, Inc. (Nasdaq: PULM), a biopharmaceutical firm that concentrates on specialized drug delivery platforms. The collaboration aims to combine resources, with significant financial implications as highlighted by the stock exchange listing on Nasdaq.

Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives | PULM Stock News

Pulmatrix and Cullgen are pursuing a merger, seeking approval from the China Securities Regulatory Commission. They have waived the 'No Solicitation' clause to explore alternative transactions. Pulmatrix's stockholders approved the merger, but CSRC approval is pending. Pulmatrix's iSPERSE™ technology is highlighted, with clinical assets like PUR3100 and PUR1800 in development. The company's cash position is sufficient to fund operations into Q4 2026.

Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets | PULM Stock News

Pulmatrix, Inc. (Nasdaq: PULM) announced its third quarter 2025 financial results and a divestment plan for its iSPERSE™ technology and related clinical programs as part of a proposed merger with Cullgen. The merger aims to create a Nasdaq-listed company focused on targeted protein degradation therapies. Pulmatrix's iSPERSE™ technology, which enhances drug delivery for treating migraine and respiratory diseases, includes 146 granted patents and 50 pending applications. The company is also advancing its PUR3100 and PUR1800 clinical programs, with PUR3100 ready for Phase 2 trials for acute migraine treatment.

Pulmatrix, Inc. SEC 10-Q Report

Pulmatrix, Inc. has released its Form 10-Q report for Q3, highlighting a revenue drop to $0 million from $7.8 million due to the wind down of the PUR1900 trial. The company reported a loss from operations of $(4.3) million, an improvement from $(7.8) million last year. Key developments include ongoing product pipeline advancements for migraine and respiratory diseases, a merger agreement with Cullgen Inc., and continued investment in intellectual property. Future operations hinge on the merger's success, with potential dissolution if not completed.

Pulmatrix | 10-Q: FY2025 Q3 Revenue: USD 0